362 related articles for article (PubMed ID: 32677680)
1. Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis.
Zhang L; She ZG; Li H; Zhang XJ
Clin Sci (Lond); 2020 Jul; 134(13):1775-1799. PubMed ID: 32677680
[TBL] [Abstract][Full Text] [Related]
2. Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis.
Xu X; Lu L; Dong Q; Li X; Zhang N; Xin Y; Xuan S
Lipids Health Dis; 2015 Dec; 14():158. PubMed ID: 26631018
[TBL] [Abstract][Full Text] [Related]
3. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
4. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors.
Mann JP; Carter P; Armstrong MJ; Abdelaziz HK; Uppal H; Patel B; Chandran S; More R; Newsome PN; Potluri R
PLoS One; 2020; 15(10):e0241357. PubMed ID: 33108366
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma and non-alcoholic fatty liver disease.
Golabi P; Rhea L; Henry L; Younossi ZM
Hepatol Int; 2019 Nov; 13(6):688-694. PubMed ID: 31701393
[TBL] [Abstract][Full Text] [Related]
8. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
9. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
Johnston MP; Patel J; Byrne CD
Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders.
Lim S; Oh TJ; Koh KK
Int J Cardiol; 2015 Dec; 201():408-14. PubMed ID: 26310987
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease represents a greater metabolic burden in patients with atherosclerosis: A cross-sectional study.
Han J; Wang Y; Yuan Z; Liu L; Zhao M; Guan Q; Zhang H; Li Q; Xu J; Gao L; Zhao J; Zhang X
Medicine (Baltimore); 2019 Mar; 98(11):e14896. PubMed ID: 30882706
[TBL] [Abstract][Full Text] [Related]
12. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.
Santos RD; Valenti L; Romeo S
Atherosclerosis; 2019 Mar; 282():110-120. PubMed ID: 30731283
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review.
Stahl EP; Dhindsa DS; Lee SK; Sandesara PB; Chalasani NP; Sperling LS
J Am Coll Cardiol; 2019 Mar; 73(8):948-963. PubMed ID: 30819364
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease.
Brea Á; Pintó X; Ascaso JF; Blasco M; Díaz Á; González-Santos P; Hernández Mijares A; Mantilla T; Millán J; Pedro-Botet J;
Clin Investig Arterioscler; 2017; 29(3):141-148. PubMed ID: 27692633
[TBL] [Abstract][Full Text] [Related]
15. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
Bertot LC; Adams LA
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic fatty liver disease and cardiovascular disease.
Hyogo H; Chayama K; Yamagishi S
Curr Pharm Des; 2014; 20(14):2403-11. PubMed ID: 23844815
[TBL] [Abstract][Full Text] [Related]
17. Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis.
Kasumov T; Li L; Li M; Gulshan K; Kirwan JP; Liu X; Previs S; Willard B; Smith JD; McCullough A
PLoS One; 2015; 10(5):e0126910. PubMed ID: 25993337
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
19. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Doumas M; Imprialos K; Stavropoulos K; Athyros VG
Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
[TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
